Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

PharmaCyte Biotech, Inc. (PMCB)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.2400-0.0200 (-0.88%)
At close: 04:00PM EDT
2.3100 +0.07 (+3.12%)
After hours: 06:08PM EDT
Advertisement
Sign in to post a message.
  • J
    JOHN
    longboarder and son doing kenny see picture below
  • P
    Paul
    Iroquois don’t trust them . Why? Because they found out money is going into Boards pockets. Iroquois putting one person of trust and integrity on board. Certainly shows lake of trust . Jmo
  • A
    Anonymous
    luv ya Irondiquios
  • o
    oscar
    Well, that response generated a lot of activity in the stock price.. so does anyone believe management? I do not think so. It is time to get rid of the 3 amigos!!!!

    At least they listened to Iroqouis but talk is cheap and PMCB had its pre-IND meeting in january of 2017-yes thats 2017.

    We still do not know when the IND will be completed. This management team just doesn't get it.
  • c
    curt
    Hey if goes up over 3.5 I can sell and be able to pay the commission for dumping it
  • K
    Keep On Trucking
    hmmm interesting going forward. A #$%$ match that could actually be for real! One never knows here . Iriquois apparently didn't do much in the way of DD and has buyers remorse.
  • l
    livendi
    dont forget that 1 golden share phead kw can have reissued by bod to keep this scam going,God bless all and good luck 2
  • J
    Jerry
    repurchasing??? all this co want to do is get back all their stock and perhaps pay you all next to nothing back. looks like reverse purchase. Maybe i'm wrong. Your comments...
  • h
    hugo
    PharmaCyte Biotech to Implement $10-Million Share Repurchase Program :)
  • J
    JL
    On April 7, 2022, the Board of Directors (“Board”) of PharmaCyte Biotech, Inc., a Nevada corporation (“Company”), approved the recommendation of the Company’s
    Compensation Committee and increased the base compensation of Kenneth L. Waggoner, the Company’s Chief Executive Officer, President and General Counsel from
    $375,000 to $520,000 per annum and increased the base compensation of Carlos Trujillo, the Company’s Chief Financial Officer, from $275,000 to $380,000 per annum, in
    each case retroactive to January 1, 2022.
  • J
    James
    Share holders should storm PMCB
    Las Vegas facility and demand Answers. Then set up camps At the personal properties
    of PMCB executives, again to demand Answers . Good luck share holders. I believe you will need it
    Bearish
  • S
    Sly  Dog
    Don't Worry - Ken Will Do It Again $5.00 + + + +
  • J
    James
    PMCB stock buyback funds
    Bearish
  • A
    Anatolian
    Kenny pumping ascites again?

    "The planned series of studies will build on previous data obtained by Prof. Matthias Löhr of the Karolinska Institute in Stockholm, Sweden, and his colleagues that showed PharmaCyte’s treatment for pancreatic cancer can slow the production and accumulation of malignant ascites. "

    There was an article Lohr submitted in 2007. So what did the study really show? Lohr injected a mouse strain of colon cancer cells into mice. Two days later they injected the magic CIABs+Ifosfamide, and in the other group injected Ifosfamide. Then on day 5 after inoculating the cancer cells in a new batch of mice.

    "Early i.p. treatment with ifosfamide and CYP2B1 cells resulted in a complete response. Treatment starting on day five and single-drug treatment with ifosfamide resulted in a partial response."

    https://pubmed.ncbi.nlm.nih.gov/17633075/

    So what would be the response against pancreatic cancer metastasis, in the liver causing ascites? A little more complicated than a mouse model. What would be the meaning of early treatment, when micro-metastasis is present in 80% of PC patients at the time of diagnosis?

    Then 9 yrs later in 2016 one has the introduction of : Hyperthermic intraperitoneal chemotherapy (HIPEC) and early post-operative intraperitoneal chemotherapy (EPIC)... Google it. As has been the case in the past science does not stand still. PMCB decades behind, pumping away.
    The prognosis of peritoneal spread from gastrointestinal cancer and subsequent malignant ascites is poor, and current medical treatments available are mostly ineffective. Targeted chemotherapy with intraperitoneal prodrug activation may be a benefici
    The prognosis of peritoneal spread from gastrointestinal cancer and subsequent malignant ascites is poor, and current medical treatments available are mostly ineffective. Targeted chemotherapy with intraperitoneal prodrug activation may be a benefici
    pubmed.ncbi.nlm.nih.gov
  • J
    James
    Class Action Lawsuits very soon. Maybe we can get .00001 of our lost investment recovered. Or partial timeshare of recovered properties, such as large expensive homes, yachts, sports cars, etc.....
  • M
    Michael
    It's Official, they committed to more turning of the screws to investors.
    Bearish
  • o
    oscar
    According to PMCB, they are working with their legal team to issue a public reply to Iroquois' open letter to PMCB BOD.

    How long can that take??? hahaha
  • J
    James
    PMCB press release by management
    Bearish
  • r
    retired
    Apparently the stock is not trading while reacting to the repurchase?
  • J
    James
    PMCB needs two more years to the case stu
    dy so then they can begin the preliminary study of the potential restudy of the first intial study. Good Luck Shareholders
    Bearish
Advertisement
Advertisement